CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Sarah Cannon, Washington University in St. Louis, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Massachusetts General Hospital, AdventHealth Orlando, AdventHealth, Henry Ford Health, Cedars-Sinai Medical Center, Fox Chase Cancer Center, The Ohio State University, University of California, Irvine, UC Irvine Chao Family Comprehensive Cancer Center, University of Colorado Cancer Center, The University of Texas MD Anderson Cancer Center, Levine Cancer Institute
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3124759341